{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Negative+Breast+Carcinoma&page=29",
    "query": {
      "condition": "HER2-Negative Breast Carcinoma",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 691,
    "total_pages": 70,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Negative+Breast+Carcinoma&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Negative+Breast+Carcinoma&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T07:42:20.789Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02032823",
      "title": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1837,
      "start_date": "2014-04-22",
      "completion_date": "2029-05-28",
      "has_results": true,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 368,
      "location_summary": "Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02032823"
    },
    {
      "nct_id": "NCT00915603",
      "title": "Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2009-07",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2014-12-22",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 15,
      "location_summary": "LaVerne, California • Norwich, Connecticut • Aventura, Florida + 11 more",
      "locations": [
        {
          "city": "LaVerne",
          "state": "California"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00915603"
    },
    {
      "nct_id": "NCT04862663",
      "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced (Inoperable) or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 893,
      "start_date": "2021-05-10",
      "completion_date": "2029-08-14",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 40,
      "location_summary": "Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Napa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04862663"
    },
    {
      "nct_id": "NCT06757634",
      "title": "Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Arm A: Gedatolisib + Palbociclib + Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Arm B: Ribociclib + Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Arm C: Gedatolisib + Palbociclib + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Arm D: Ribociclib + Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celcuity Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1180,
      "start_date": "2025-07-24",
      "completion_date": "2033-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 30,
      "location_summary": "Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06757634"
    },
    {
      "nct_id": "NCT07218432",
      "title": "A Study of the TheraBionic P1 Device in Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer Stage I",
        "Breast Cancer Stage II",
        "Breast Cancer Stage IIIA",
        "Hormone Receptor Positive Tumor",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TheraBionic P1 Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "22 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2026-10",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 8,
      "location_summary": "Clarkston, Michigan • Detroit, Michigan • Farmington Hills, Michigan + 5 more",
      "locations": [
        {
          "city": "Clarkston",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Flint",
          "state": "Michigan"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218432"
    },
    {
      "nct_id": "NCT02088684",
      "title": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        },
        {
          "name": "BYL719",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "BKM120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2014-05-19",
      "completion_date": "2018-04-17",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02088684"
    },
    {
      "nct_id": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Renal Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Triple Negative Breast Cancer",
        "HR+/HER2- Breast Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 557,
      "start_date": "2016-12-19",
      "completion_date": "2022-04-28",
      "has_results": true,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 22,
      "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983045"
    },
    {
      "nct_id": "NCT02208375",
      "title": "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BRCA1 Mutation Carrier",
        "BRCA2 Mutation Carrier",
        "Endometrial Adenocarcinoma",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vistusertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 159,
      "start_date": "2014-11-11",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02208375"
    },
    {
      "nct_id": "NCT02018458",
      "title": "Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LA TNBC: DC vaccine+Preop chemo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ER+/HER2-BC:DC vaccine+Preop chemo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2014-05",
      "completion_date": "2019-09-18",
      "has_results": true,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02018458"
    },
    {
      "nct_id": "NCT05115474",
      "title": "Study of Screening Brain MRIs in Stage IV Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "HER2-positive Breast Cancer",
        "Hormone Receptor-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Magnetic Resonance Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2021-12-21",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-22T07:42:20.789Z",
      "location_count": 2,
      "location_summary": "Clearwater, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05115474"
    }
  ]
}